We screened for novel circuits in the mouse brain that promote wakefulness. Chemogenetic activation experiments and electroencephalogram recordings pointed to glutamatergic/nitrergic (NOS1) and GABAergic neurons in the ventral tegmental area (VTA). Activating glutamatergic/NOS1 neurons, which were wake-and rapid eye movement (REM) sleep-active, produced wakefulness through projections to the nucleus accumbens and the lateral hypothalamus. Lesioning the glutamate cells impaired the consolidation of wakefulness. By contrast, activation of GABAergic VTA neurons elicited long-lasting non-rapideye-movement-like sleep resembling sedation. Lesioning these neurons produced an increase in wakefulness that persisted for at least 4 months. Surprisingly, these VTA GABAergic neurons were wake-and REM sleep-active. We suggest that GABAergic VTA neurons may limit wakefulness by inhibiting the arousal-promoting VTA glutamatergic and/or dopaminergic neurons and through projections to the lateral hypothalamus. Thus, in addition to its contribution to goal-and reward-directed behaviors, the VTA has a role in regulating sleep and wakefulness.
W e still do not know all of the circuitry in mammals regulating wakefulness and sleep [1] [2] [3] [4] . Broadly, wakefulness is promoted by ascending aminergic and peptidergic systems 1, [5] [6] [7] [8] . GABAergic and glutamatergic pathways can also induce wakefulness and physical activity [9] [10] [11] [12] [13] [14] [15] [16] [17] . On the other hand, sleep is promoted by GABAergic/peptidergic and glutamatergic/nitrergic neurons that inhibit the wake-promoting neurons 3, [18] [19] [20] [21] [22] [23] . Here, we describe a non-hypothesis-driven chemogenetic search for further circuitry controlling vigilance states, and unexpectedly converge on the VTA. The VTA is intensively investigated for its regulation of goal-and reward-directed and social behaviors [24] [25] [26] [27] [28] . As well as dopamine neurons (VTA DA ), the VTA contains GABAergic and glutamatergic neurons, which independently project out of the VTA 24, 29, 30 . These GABA and glutamate neurons are believed to control reward-and goal-directed and social behaviors 31, 32 . These behaviors require wakefulness, and indeed VTA DA neurons are selectively wake-and rapid eye movement (REM) sleep-active, and actually promote wakefulness 5, 8, 33 . Complimenting this work, we find that VTA glutamate/NOS1 and GABA neurons increase and decrease wakefulness, respectively. The VTA is, therefore, a node whose circuitry potently influences vigilance state.
Results
A chemogenetic search for glutamatergic circuitry enhancing wakefulness. We searched for glutamatergic neurons in the posterior hypothalamic-midbrain area (PH/MB) that could promote wakefulness (Fig. 1) . By injecting adeno-associated virus (AAV)-DIO-hM3Dq-mCherry into Vglut2-ires-Cre mice, we expressed the excitatory hM3Dq DREADD receptor in Vglut2 neurons in progressively more defined locations (Fig. 1 ). (Note: for the following series of experiments, clozapine-N-oxide (CNO; 1 mg kg −1 ) was injected intraperitoneally (i.p.) at the start of 'lights on' , when the mice had their maximal sleep drive. Injecting CNO (1 mg kg −1 ) i.p. into AAV-naïve Vglut2-ires-Cre mice-that is, mice not injected with AAV-did not produce any changes in the amounts of sleep or wakefulness ( Supplementary Fig. 1a ). ) We obtained dramatic results from large-volume injections of AAV-DIO-hM3Dq-mCherry into the PH/MB of Vglut2-iresCre mice ((PH/MB) L
Vglut2
-hM3Dq mice) (Fig. 1a) . Following CNO injections, 100% wakefulness was induced for 12 h compared with saline-injected control mice (Fig. 1b, 
c). In these (PH/MB) L

Vglut2
hM3Dq mice, hM3Dq-mCherry receptor expression (determined by mCherry staining) was found throughout the lateral hypothalamus (LH), dorsal medial hypothalamus, ventral medial hypothalamus, mammillary area, tuberomammillary area, supramammillary area, VTA, and interpeduncular nucleus (IPN). A smaller AAV injection volume into the PH/MB of Vglut2-ires-Cre mice resulted in hM3Dq expression in the LH, mammillary area, and VTA ((PH/ MB) S
-hM3Dq mice, see Fig. 1d ). CNO i.p. injection into these (PH/MB) S
-hM3Dq mice produced continuous wakefulness for approximately 5 h, followed by enhanced wakefulness for another 7 h (Fig. 1e,f) . Restricting hM3Dq expression to the LH and activating with systemic CNO also produced extended wakefulness ( Fig. 1g-i) .
By contrast, restricting hM3Dq expression to glutamatergic neurons in the mammillary area of Vglut2-ires-Cre mice ( Fig. 1j and Supplementary Fig. 2a , M
-hM3Dq mice), and giving CNO, did not produce arousal above that resulting from baseline saline injections (Fig. 1k,l AAV-DIO-hM3Dq-mCherry was injected into different areas of the brain of Vglut2-ires-Cre mice. AAV expression was determined by immunocytochemistry for mCherry (red). The images show the actual mCherry staining. a-c, AAV injection into a large volume of PH/MB (PH/MB) L . The experiment in a was repeated independently five times. The graphs show percentage of wake, NREM, and REM sleep and how these states vary with saline (n = 5 mice) or CNO (n = 5 mice) i.p. injections. d-f, AAV was injected into a smaller volume of PH/MB (PH/MB) s , and sleep-wake states were scored as above after saline (n = 4 mice) or CNO (n = 5 mice) i.p. injections. The experiment in d was repeated independently five times. g-i, AAV injection was restricted to the LH, and sleep-wake states were scored following saline and CNO injection after saline (n = 6 mice) or CNO (n = 6 mice) i.p. injections. The experiment in g was repeated independently six times. j-l, AAV injection was restricted to the mammillary area, and sleep-wake states scored following saline (n = 7 mice) and CNO (n = 7 mice) i.p. injection. The experiment in j was repeated independently five times. See Supplementary Fig. 2a for examples of hM3Dq-mCherry expression in individual mice. m-o, AAV injection was restricted to the IPN, and sleep-wake states were scored following saline (n = 6 mice) and CNO (n = 7 mice) i.p. injection. The experiment in m was repeated independently six times. See Supplementary Fig. 2b for examples of individual hM3Dq-mCherry expression. p-r, AAV injection was restricted to the VTA, and sleep-wake states were scored following saline (n = 6) and CNO (n = 6) i.p. injection. The experiment in p was repeated independently six times. See Supplementary Fig. 2c for examples of hM3Dq-mCherry expression in individual mice. DMH, dorsomedial hypothalamus; Mm, medial mammillary area; TMN, tuberomammillary area; VMH, ventromedial hypothalamus. All error bars represent the s.e.m. **P < 0.01, ***P < 0.001, ****P < 0.0001; two-sided unpaired t test. For detailed statistical information, see Supplementary Table 1 .
Articles Nature NeuroscieNce IPN of Vglut2-ires-Cre mice ( Fig. 1m and Supplementary Fig. 2b , IPN
-hM3Dq mice), and subsequent injection of CNO, also did not elicit arousal compared with saline injection (Fig. 1n,o) .
Glutamatergic neurons in the VTA produce wakefulness. We next limited hM3Dq receptor expression to the VTA of Vglut2-ires-Cre mice to make VTA Vglut2 -hM3Dq mice ( Fig. 1p and Supplementary  Fig. 2c ). Following 1 mg kg −1 CNO i.p. injection, there was 5 h of 100% wakefulness; the extent of wakefulness remained elevated for nearly the entire 'lights on' period (Fig. 1q,r) . (Note: as a further control for the specificity of CNO's actions, we injected AAV-DIOmCherry into the VTA of Vglut2-ires-Cre mice; CNO injection (i.p.) into these VTA Vglut2 -mCherry mice had no effect on the amounts of sleep or wakefulness ( Supplementary Fig. 1c) .)
Of the brain regions that we injected, the VTA Vglut2 population that promotes wakefulness had not to our knowledge previously been identified in this role, and so we decided to study these cells in detail. We first confirmed that these neurons were excited by CNO in VTA Vglut2 -hM3Dq mice. One h after CNO i.p. injection into VTA Vglut2 -hM3Dq mice, cFos protein was elevated in hM3Dq-expressing VTA Vglut2 neurons (saline: 41 ± 4, CNO: 378 ± 36 cFos-positive cells), confirming excitation of VTA Vglut2 neurons ( Supplementary Fig. 2d ). Looking at the CNO-evoked electroencephalogram (EEG) spectra of VTA Vglut2 -hM3Dq mice ( Supplementary Fig. 2e ), the excitation of VTA Vglut2 neurons produced higher theta (8 Hz) activity ( Supplementary Fig. 2f ) but the electromyogram (EMG) signal did not change ( Supplementary  Fig. 2f ). Activation of VTA Vglut2 neurons also strongly increased the latency to both non-rapid eye movement (NREM) and REM sleep ( Supplementary Fig. 2g ). However, excitation of VTA Vglut2 neurons did not cause hyperactivity ( Supplementary Fig. 2h) . In an open field assay, the CNO-injected (i.p.) mice did not move further than saline-injected mice, but stayed awake for an extended period.
Confirming the behavioral effects of the chemogenetic activation of VTA Vglut2 neurons, optogenetic activation of VTA Vglut2 neurons with ChR2 also increased wakefulness ( Supplementary Fig. 3a-c) .
VTA
Vglut2 neurons consolidate wakefulness during the sleep-wake cycle. To investigate how VTA Vglut2 neurons influence the sleepwake cycle over 24 h, we genetically ablated VTA Vglut2 neurons using AAV-DIO-CASP3 to produce VTA Vglut2 -CASP3 mice ( Fig. 2a and Supplementary Fig. 3d ). About 80% of the VTA Vglut2 neurons were destroyed ( Supplementary Fig. 3d ). Chronic lesioning of VTA Vglut2 cells reduced wakefulness, and increased NREM sleep, but only during the 'lights off ' phase (Fig. 2b) . Looking at the sleep-wake microarchitecture, wake consolidation was impaired, with more episodes and shorter episode durations of wake (Fig. 2c) , and with more transitions between wake and NREM sleep (Fig. 2d) , again with the phenotype appearing selectively during 'lights off ' .
Vglut2 neurons are selectively wake-and REM sleep-active. To determine when during the natural sleep-wake cycle the VTA Vglut2 neurons were active, we made VTA
Vglut2
-GCaMP6 mice (Fig. 2e) , then recorded Ca 2+ signals by fiber photometry ( Fig. 2f  and Supplementary Fig. 3e ). (Note: we used GCaMP6s for all of this and all subsequent photometry experiments.) The Ca 2+ signal increased selectively during wakefulness and REM sleep (Fig. 2f,g ), and with novel objects and female scents ( Supplementary Fig. 3e ). During NREM sleep, the VTA Vglut2 neurons had lower Ca 2+ signals (Fig. 2f,g ). At the transitions between the vigilance states, the ratio of the change in fluorescence intensity relative to the resting baseline fluorescence intensity (Δ F/F ratio) increased from NREM to wake and from NREM to REM sleep (Fig. 2h) , but decreased from wakefulness to NREM. The Δ F/F ratio changed little during REM sleep to wake transitions (Fig. 2h) . (As controls, no changes in the Δ F/F ratio were found by photometry between vigilance states in VTA
-GFP mice ( Supplementary Fig. 3f,g ); furthermore, there was no bleaching of the signal in VTA
-GCaMP6s mice, as the Δ F/F ratios stayed constant over 6 h ( Supplementary Fig. 3h ).)
VTA
Vglut2 neurons promote wakefulness independently of dopamine. Dopamine neurons in the VTA promote wakefulness 5, 8 , so we tested whether the wake-promoting effect of VTA Vglut2 neurons depended on dopamine. We first verified that VTA
Vglut2
neurons are largely distinct from VTA dopamine neurons. Immunohistochemistry confirmed that only 26 ± 1.6% of the Vglut2 cells were tyrosine hydroxylase-positive ( Supplementary Fig. 4a,b) , as shown previously 24 . Unlike dopamine neurons, VTA Vglut2 cells were mostly located in the midline VTA nuclei-the rostral linear nucleus and the interfascicular nucleus ( Supplementary Fig. 4b ) 24, 34 . Thus, the majority of VTA Vglut2 and VTA DA neurons are distinct populations. We next chemogenetically activated the VTA Vglut2 neurons in VTA
hM3Dq mice with CNO in the presence of systemically administered dopamine antagonists SCH-23390 and raclopride for D1 and D2/D3 receptors, respectively ( Supplementary Fig. 4c,d ) (note: mice were injected i.p. with the dopamine receptor antagonists 30 minutes before CNO i.p. injection-please see Methods for drug concentrations). Even when dopamine receptors were blocked, VTA Vglut2 neurons still promoted wakefulness ( Supplementary Fig. 4d ).
VTA
Vglut2 neurons promote wakefulness via the nucleus accumbens (NAc) and the LH. To identify the brain areas that participate in generating the VTA
Vglut2
-mediated wakefulness, we mapped cFos activity in VTA Vglut2 -hM3Dq mice. Following CNO i.p. injection, increased numbers of cFos-positive cells were identified in multiple 
-GFP mice (n = 7 mice) and VTA
-CASP3 mice (n = 8 mice), and the total vigilance times in the 'lights on' and 'lights off' periods. c,d, Lesioning of VTA Vglut2 neurons. Episode number and duration for wake, NREM, and REM sleep, and vigilance state transitions during the 'lights off' periods in VTA
-GFP control mice (n = 7 mice) and VTA
-CASP3 mice (n = 8 mice). e, Fiber photometry for VTA Vglut2 neurons. Injection of AAV-DIO-GCaMP6 into the VTA of the Vglut2-ires-Cre mice. The experiment was repeated independently seven times. GCaMP6 expression can be detected in the VTA area and the trace of where the optical fiber was placed is marked. f, Fiber photometry Ca 2+ spectra (bottom trace) recorded in the VTA of VTA
-GCaMP6 mice aligned with the EEG (middle trace) and EMG (top trace) spectra during wakefulness, NREM, and REM sleep. 'Epoch' indicates vigilance state: blue, wake; green, NREM sleep; magenta, REM sleep. g, Fiber photometry Δ F/F ratio of the Ca 2+ signal in VTA
-GCaMP6 mice during wakefulness, NREM sleep, and REM sleep (n = 7 mice; 38 sessions). h, Detail of how the Ca 2+ photometry signal in Vglut2 neurons of VTA Vglut2 -GCaMP6 mice changes at the boundaries of the vigilance states (n = 7 mice). Ca 2+ photometry Δ F/F ratio (bottom trace) in the VTA
-GCaMP6 mice aligned with the extracted δ power in the EEG, the EEG spectrum itself, and EMG during wakefulness, NREM, and REM sleep. 'Epoch' indicates vigilance state as in f. Gray-shaded regions represent s.e.m. *P < 0.05, **P < 0.01, ****P < 0.0001; for b-d, two-sided unpaired t test; for g, one-way analysis of variance (ANOVA Articles Nature NeuroscieNce brain regions (Fig. 3a and Supplementary Fig. 5a,b) . cFos expression was particularly activated in the LH, NAc, and ventral pallidum ( Fig. 3a and Supplementary Fig. 5a,b) . In the LH, 60% of cFosexpressing cells that were activated by CNO i.p. injections were also orexin-positive compared with the low number of cFos-expressing cells following saline injection (Supplementary Fig. 5c ).
We then undertook ChR2-based circuit mapping of the VTA Vglut2 neurons in VTA
-ChR2-EYFP mice ( Fig. 3b and Supplementary  Fig. 5d ). Consistent with the cFos activation data, there was a dense projection of VTA Vglut2 neurons to the LH and NAc ( Fig. 3b and Supplementary Fig. 5c ), as described previously 29, 30, 35, 36 . To test whether the VTA 
Vglut2-Cre
µm
Articles Nature NeuroscieNce can promote wakefulness, we placed optical fibers into the LH and NAc of VTA
Vglut2
-ChR2-EYFP mice to stimulate the terminals (Fig. 3c-f ). Optically stimulating VTA Vglut2 fibers in the LH strongly and consistently promoted waking from NREM sleep ( Fig. 3c and Supplementary Fig. 6a) ; chronic optical stimulation for 3 h maintained wakefulness (Fig. 3d) . Similarly, optogenetic stimulation of the VTA Vglut2 terminals in the NAc promoted waking from NREM sleep ( Fig. 3e and Supplementary Fig. 6b ) and chronic optogenetic stimulation for 3 h increased wakefulness and reduced NREM and REM sleep (Fig. 3f) . Thus, the LH and NAc are two areas contributing to wakefulness when excited by VTA Vglut2 neurons.
Nitric oxide synthase marks wake-promoting VTA Vglut2 neurons. To confirm the wake-promoting actions of the VTA Vglut2 → LH and VTA
→ NAc projections, we used retrograde-labeling by injecting AAV-Retro-DIO-Chronos-GFP into the LH and NAc of Vglut2-ires-Cre mice. We identified many green fluorescent protein (GFP)-positive soma in the VTA ( Supplementary Fig. 7a,b) . We optogenetically activated the Chronos-GFP retro-labeled cells by inserting optical fibers into the VTA (Supplementary Fig. 7b ). Tonic opto-activation increased cFos in these retro-labelled neurons (control: 31 ± 5, stimulation: 206 ± 41) ( Supplementary Fig. 7c ). Activation of the retro-labeled NAc→ VTA Vglut2 neurons increased wakefulness ( Supplementary Fig. 7d ). To profile these retrolabeled VTA Vglut2 neurons, we stained VTA Vglut2 neurons with a panel of antibodies recognizing neurochemical markers (nitric oxide synthase (NOS1), tyrosine hydroxylase, glutamic acid decarboxylase (GAD67), parvalbumin, somatostatin) ( Fig. 4a and Supplementary Fig. 7e ). Of these markers, double-labeling of retrolabeled NAc→ VTA Vglut2 and LH→ VTA Vglut2 neurons identified that about 68 ± 9% of the GFP-positive cells were immuno-positive for NOS1 ( Fig. 4a and Supplementary Fig. 7f ), mostly in the midline VTA. This was confirmed by direct double-labeling with VTA Vglut2 -ChR2-EYFP neurons and VTA Nos1 neurons ( Supplementary  Fig. 8a,b) . About 75 ± 3% of VTA Nos1 cells were VTA
-positive ( Supplementary Fig. 8b ), as also seen independently 34 .
To test whether the VTA Nos1 neurons are functionally the same as the VTA Vglut2 neurons in producing wakefulness, we chemogenetically activated the VTA Nos1 neurons by delivering AAV-DIOhM3Dq-mCherry into the VTA of Nos1-ires-Cre mice (Fig. 4b,c) . As for the VTA Vglut2 -hM3Dq mice, giving 1 mg kg −1 CNO i.p. to the VTA
Nos1
-hM3Dq mice produced sustained wakefulness (100%) for 4 h ( Fig. 4c and Supplementary Fig. 8c ). Also similar to the VTA Vglut2 -hM3Dq mice, the wakefulness produced by i.p.-administered CNO activation of VTA Nos1 neurons was not blocked by systemic i.p.-administered dopamine D1 and D2/D3 receptor antagonists ( Supplementary Fig. 8d) Supplementary Fig. 8f ), again implying that the NOS1-expressing neurons are a subset of the glutamatergic ones.
VTA
Vgat neurons limit wakefulness and induce NREM sleep. We next looked for neurons in the VTA that could potentially restrain the wake-promoting activity of the VTA Vglut2/Nos1 neurons. The VTA contains many GABAergic neurons ( Supplementary Fig. 9a ,b) 24, 30 . These can be detected by expression of the vesicular GABA transporter (VGAT). We first confirmed that Vgat gene-expressing neurons were mostly distinct from dopamine or glutamate neurons: only 0.3 ± 0.1% of these GABAergic neurons (as defined by VTA Vgat -ChR2-EYFP staining) stained with tyrosine hydroxylase ( Supplementary Fig. 9a ), and 12 ± 0.6% of these VTA Vgat neurons were NOS1-positive; however, these cells were not in the midline but mostly in the lateral part of the VTA (parabrachial pigmented nucleus, PBP), which is distinct from VTA Nos1/Vglut2 populations in the midline ( Supplementary Fig. 9b ) 34 .
To examine whether VTA
Vgat neurons contribute to sleep-wake regulation, AAV-DIO-hM3Dq-mCherry or AAV-DIO-hM4D imCherry was injected into the VTA of Vgat-ires-Cre mice to generate VTA Vgat -hM3Dq and VTA Vgat -hM4D i mice, respectively ( Fig. 5a and Supplementary Fig. 9c,d ). CNO injection i.p. into VTA Vgat -hM3Dq mice produced sustained (80%) NREM sleep for 6 h (Fig. 5b) , with continuous δ power in the EEG. Following CNO administration i.p., the latency to NREM sleep was reduced to about 10 minutes compared with saline administration (Fig. 5c ). However, latency to REM sleep was notably increased-there was no REM sleep in the first 6 h (Fig. 5c ). (Note: we did several further controls for the specificity of CNO's actions to ensure it was not acting as a sedative after conversion to clozapine 37 . We injected 1 mg kg −1 CNO i.p. into both AAV-naïve Vgat-ires-Cre mice-that is, mice that had not received any AAV injections ( Supplementary Fig. 1b )-and into VTA Vgat -mCherry mice (produced by injecting AAV-DIO-mCherry into the VTA of Vgat-ires-Cre mice). In neither of these types of mice did CNO alter the amounts of sleep or wakefulness compared with saline-injected controls ( Supplementary Fig. 1d ). In a separate study 21 , we similarly found that CNO systemically injected i.p. at the higher concentration of 5 mg kg −1 into AAV-naïve Vgat-ires-Cre 
Vglut2
-hM3Dq mice, labeled axons mainly project from the VTA to the LH and NAc. cFos protein expression in neurons of the LH and NAc of VTA
-hM3Dq mice 2 h after saline or CNO i.p. injection at zeitgeber time (ZT) 0. The red in the histology figure is the primary fluorescence of the hM3Dq-mCherry-positive axons coming from the VTA area; the cFos immunohistochemistry is shown in green. The experiment was repeated independently six times. CPu, caudate-putamen; MS, medial septum; PeF, perifornical area; 3V, third ventricle; VP, ventral pallidum. b, Axonal projections of VTA Vglut2 neurons. AAV-DIO-ChR2-EYFP was delivered into the VTA of Vglut2-ires-Cre mice, and axons projecting to the LH and NAc were strongly labeled. The experiment was repeated independently four times. TH, tyrosine hydroxylase. c,d, To functionally investigate the VTA
→ LH projection, an optical fiber was placed into the LH area of VTA
-ChR2-EYFP mice. c, Mice were given 120 s of optostimulation (20 Hz) during NREM sleep ('lights on' period) and the percentages and times for wake and NREM were scored (control: n = 6 mice, 23 trials; ChR2: n = 6 mice, 21 trials). d, VTA
-ChR2-EYFP mice (control: n = 8 mice; ChR2: n = 8 mice) were given 3 h of optostimulation at the start of the sleep period ('lights on' period) and the percentages and times for wake, NREM, and REM sleep were scored. e,f, To functionally investigate the VTA
→ NAc projection, an optical fiber was placed into the NAc area of VTA
-ChR2-EYFP mice. e, Mice were given 120 s of optostimulation (20 Hz) during NREM sleep ('lights on' period) and the percentages and times for wake and NREM were scored (control: n = 9 mice, 21 trials; ChR2: n = 10 mice, 20 trials). f, VTA
-ChR2-EYFP mice (control: n = 6 mice; ChR2: n = 6 mice) were given 3 h of optostimulation at the start of sleep ('lights on' period) and the percentages and times for wake, NREM, and REM sleep were scored. **P < 0.01, ***P < 0.001, ****P < 0.0001; for c and e, two-sided Mann-Whitney U test; for d and f, two-sided unpaired t test. All error bars represent the s.e.m. For c and e, the shaded region represents s.e.m. For detailed statistical information, see Supplementary Table 1 .
Articles Nature NeuroscieNce mice also did not induce NREM sleep above the background of sleep occurring following saline injection 21 .) In converse experiments with chemogenetic inhibition of VTA Vgat neurons, injecting CNO i.p. into VTA Vgat -hM4D i mice produced 100% wakefulness for 6 h with sustained theta frequencies in the EEG (Fig. 5d ). There was an increased latency to the first NREM and REM sleep bouts to > 6 h post-injection of CNO i.p. compared with saline i.p.-injected mice (Fig. 5e ).
We next examined whether subtypes of GABAergic neurons can induce NREM sleep. Subtypes of GABAergic neurons in the VTA include those expressing parvalbumin (Pv), somatostatin (Som), and, in the PBP region, Nos1/Vgat 34 (see also Supplementary  Fig. 9b ). We chemogenetically activated VTA Fig. 10 ). Thus, several GABAergic subtypes in the VTA can contribute to induction of NREM sleep, although each group activated individually does not give the full effect obtained with activating VTA Vgat neurons.
Lesioning of VTA Vgat neurons produces continuous wakefulness. To look at VTA
Vgat function in the sleep-wake cycle over 24 h, we chronically lesioned VTA Vgat neurons with AAV-DIO-CASP3 ( Fig. 6a and Supplementary Fig. 11a ). About 88% of the VTA Vgat neurons were destroyed ( Supplementary Fig. 11a ). In these VTA Vgat -CASP3 mice, there was an increase in wakefulness in both the 'lights on' and 'lights off ' periods, but especially during the 'lights off ' period-the VTA Vgat -CASP3 animals slept for only 40 minutes, whereas non-lesioned VTA Vgat -GFP control mice slept 4 h in the 12 h of the 'lights off ' period (Fig. 6b) . During 'lights on' , the least active period of the mice, the control mice slept for about 7 h, and the VTA Vgat -CASP3 mice slept for about 6 h (Fig. 6b) . During 'lights off ' , the average NREM episode duration of VTA Vgat -CASP3 mice was much shorter, and transitions between vigilance states were dramatically decreased (Fig. 6c,d) . The reduced sleep phenotype of VTA Vgat -CASP3 persisted unchanged for at least 4 months, Supplementary Fig. 11b ).
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Nature NeuroscieNce resulting in the mice having a permanent and substantial sleep deficit (
VTA
Vgat neurons are selectively wake-and REM-active. (Fig. 6e) . Surprisingly, as for the Vglut2 neurons, we found that the Ca 2+ signal for the VTA Vgat neurons actually increased selectively during wakefulness and REM sleep (Fig. 6f) . During NREM sleep the VTA Vgat cells had a lower Ca 2+ signal (Fig. 6f,g ). At the transitions between the vigilance states (Fig. 6h) , the Δ F/F ratio decreased from wakefulness to NREM sleep, and increased from NREM sleep to wake, and from NREM to REM sleep (Fig. 6h) . Within an individual bout of wake or REM sleep, the Ca 2+ signal of the VTA Vgat cells did not differ between the earlier and later parts of the bouts (Supplementary Fig. 11c ).
To search for NREM sleep-active VTA Vgat neurons that might have been missed by fiber photometry, we used micro-endoscopic calcium imaging of these neurons in VTA Vgat -GCaMP6f mice ( Supplementary  Fig. 12 ). We placed a gradient refractive index (GRIN) lens above the VTA, and recorded fluorescence of VTA Vgat neurons during NREM sleep or wakefulness of freely moving mice ( Supplementary Fig. 12a ). For the single cells that were tracked (16 cells from 4 mice), Ca 2+ levels in VTA Vgat neurons increased during wake and decreased during NREM sleep ( Supplementary Fig. 12b-f ). This result further confirmed that VTA Vgat neurons are selectively wake-active.
Vgat neurons reduce wakefulness and induce NREM sleep by both local inhibition and via projections to the LH. Because VTA Vgat neurons are selectively wake-and REM-on, we hypothesized that they are not physiologically triggering NREM sleep, but they are instead limiting wakefulness. To explore how VTA Vgat neurons do this, we conducted ChR2-based mapping of the projections of VTA Vgat axons by delivering AAV-DIO-ChR2-EYFP into the VTA area of Vgat-ires-Cre mice. As published previously 38 , dense VTA Vgat ChR-positive fibers were found locally in the VTA (Fig. 7a) but also in the LH area (Fig. 7a) and, to some extent, in the lateral habenula (LHb) and dentate granule cells of the hippocampus ( Supplementary  Fig. 13a ); a few fibers were also in the prefrontal cortex (PFC) and lateral preoptic area (Supplementary Fig. 13a ). The especially dense VTA Vgat fibers in the VTA indicate strong local inhibition. To test these connections, we did cFos activity mapping by inhibiting VTA Vgat neurons with 1 mg kg −1 CNO injected i.p. into VTA Vgat -hM4D i mice to examine which areas of the brain expressed cFos protein (by disinhibition). After CNO injection i.p., which promoted wakefulness (Fig. 5d) , cFos was induced strongly in the VTA and LH (Fig. 7b and Supplementary Fig. 13b,c) . Thus, based on cFos expression as a readout of neuronal excitation, VTA Vgat neurons cause inhibition by projecting to the LH, as well as local inhibition in the VTA.
We confirmed directly that VTA Vgat neurons can mediate local inhibition. We prepared acute brain slices containing the midline VTA from VTA Vgat -ChR2-EYFP mice, optogenetically activated the VTA Vgat neurons (Fig. 7c) , and observed the postsynaptic responses in non-Vgat cells. Whole-cell patch clamping confirmed that 87.5% of postsynaptic cells (14 of 16 cells) received either optogenetically evoked inhibitory postsynaptic currents (oIPSCs) only, or both oIPSCs and optogentically evoked excitatory postsynaptic currents (oEPSCs) ( (Fig. 7c) ; 12.5% of cells (2 of 16 cells) had oEPSCs only (Fig. 7c) . From the relative peak oIPSC and oEPSC ratios, most non-VGAT cells had significantly larger oIPSCs than oEPSCs (Fig. 7c) . From single-cell PCR profiling, these non-Vgat neurons with oIPSCs were a mixture of VTA (Fig. 7d) Fig. 5d ). With dopamine receptor antagonists, CNO-induced wakefulness was blocked by 20% (Fig. 7e) , implying that the sustained wakefulness originating from the inhibited VTA Vgat neurons could be partially due to the activation (disinhibition) of VTA dopamine neurons.
To test whether VTA Vgat neurons use local inhibition to restrict wakefulness, we infused the GABA A receptor antagonist gabazine (SR95531) into the VTA of CNO i.p.-injected VTA Vgat -hM3Dq mice (please see Methods for gabazine concentration) (Fig. 7f) . In the CNO-injected VTA Vgat -hM3Dq mice, gabazine reduced CNOinduced NREM sleep by 40% (Fig. 7f) . Thus, the sustained NREM sleep originating from the activated VTA Vgat neurons was partially due to local inhibition of VTA
Vglut2
, VTA DA , and VTA Vglut2/DA neurons. As blocking local GABA transmission with gabazine did not completely abolish the ability of activated VTA Vgat neurons to induce sustained NREM sleep, the projections of these VTA Vgat neurons might also contribute. We found that, following CNO inhibition of VTA Vgat neurons in VTA Vgat -hM4Di mice, the number of cFos-expressing cells in the LH was strongly elevated compared with saline injections Articles Nature NeuroscieNce (Fig. 7b) . About 50% of those Fos-positive LH cells were orexin neurons ( Supplementary Fig. 13d ). By injecting Retro-AAV-DIOChronos-GFP into the LH area of Vgat-ires-Cre mice, we also detected dense retro-labeled soma in the VTA (Supplementary Fig. 13e) .
The results imply that the VTA Vgat → LH projection participates in NREM sleep induction. We therefore placed optical fibers into the LH of VTA Vgat -ChR2-EYFP mice to stimulate the terminals of VTA Vgat neurons (Fig. 8a) . Opto-activating VTA Vgat fibers in the LH strongly and consistently initiated wake to NREM sleep transitions (Fig. 8a) ; Chronic opto-stimulation for 3 h increased NREM sleep and reduced wakefulness and REM sleep (Fig. 8b) . Moreover, activation could also maintain NREM sleep, with much longer 
Vgat-Cre
Articles Nature NeuroscieNce episode duration but without affecting REM sleep duration (Fig. 8c) , indicating that the VTA Vgat → LH projection is sufficient to promote and maintain NREM sleep. However, the EEG power did not differ (Supplementary Fig. 14) . Because cFos expression was highly elevated in the dentate granule cells (DG) when we inhibited VTA Vgat neurons ( Supplementary Fig. 13c ), we also opto-stimulated the VTA Vgat → DG projection, but did not observe any effects on sleep or wakefulness ( Supplementary Fig. 15a,b) . The above results imply that VTA Vgat neurons limit wakefulness by locally inhibiting both VTA glutamatergic and dopaminergic neurons, but also via projection targets (orexin neurons) in the LH.
Discussion
Our search for novel circuits that promote wakefulness identified wake-and REM sleep-active glutamatergic/NOS1 neurons in the VTA (see Supplementary Fig. 16 for schematic summary) . By contrast, we found that VTA GABAergic neurons, when artificially activated, produce a profound sedative state, but surprisingly these neurons, such as VTA DA and VTA Vglut2 cells, are selectively wakeand REM-active during normal sleep 5 . Because of this mismatch between physiological activity and the outcome of artificial activation, we speculate that VTA Vgat neurons do not physiologically promote natural NREM sleep, but instead restrain wakefulness. This speculation is, in our view, supported by the results of lesioning the VTA Vgat neurons (see below). Alternatively, there could be rare VTA GABAergic neurons, not detected by fiber photometry or in vivo Ca 2+ imaging, that are NREM sleep-active. Such a cell type might actively induce NREM sleep. At the moment there is no direct evidence for either idea limiting wakefulness or rare NREM-active GABA cells. There are certainly subtypes of GABA neurons in the VTA, for example Pv-and Som-expressing cells, but we found that activating these also induced NREM sleep, although each subtype activated individually does not give the full effect obtained with activating the complete set of VTA Vgat neurons. Future work needs to clarify how the subtypes of VTA Vgat neurons interact to influence sleep and wakefulness.
When VTA Vgat neurons are lesioned this causes permanent sleep loss that persists for months ( Supplementary Fig. 11b ). It will be interesting to identify metabolic changes produced by this longterm loss of sleep. The effects of the VTA Vgat and VTA Vglut2 lesionsthat is, more and less wakefulness, respectively-manifest selectively during the 'lights off '/active phase of the mice (Figs. 2b and 6a and Supplementary Fig. 11 ). This fits with multiunit recordings from mouse VTA neurons, where most cells are under circadian control and fire more during 'lights off ' 39 .
Loss of VTA
Vglut2 neurons doubles the number of NREM sleep episodes, and so fragments wakefulness. Nevertheless, the effects of the VTA Vgat lesions on wakefulness (Fig. 6b) are greater than those of lesioning VTA Vglut2 cells (Fig. 2b) . It is difficult to predict the effects of ablations. For example, histamine neurons, cholinergic neurons, and noradrenergic neurons can be triply lesioned without influencing the baseline amounts of sleep-wake 40 , yet the acute activation or inhibition of these cell groups induces large changes in vigilance state 1 . We speculate that VTA Vgat neurons are strategically important as they influence diverse targets, including VTA
Vglut2
, VTA DA , and LH-orexin neurons. Hence, the loss of VTA Vgat neurons produces large effects. The persistence of this phenotype (chronic wakefulness) post-lesion suggests that no compensation is possible, and perhaps emphasizes the importance of VTA Vgat neurons in regulating vigilance state.
We propose that VTA Vgat neurons limit wakefulness both via projections to arousal-promoting orexin neurons in the LH (Supplementary Fig. 16 ) and by inhibiting glutamate and dopamine neurons locally in the VTA. As expected 41 , we found that some midline VTA Vgat neurons corelease glutamate, although the ratio of optically evoked IPSCs to EPSCs was about 5:1 in favor of inhibition. In the LH, many (60%) of the VTA Vgat targets are orexinergic neurons, but VTA Vgat terminals could also inhibit wake-promoting GABAergic projection neurons 11, 15 .
When VTA
Vgat neurons are chemogenetically excited the duration of the evoked NREM sleep is remarkable, lasting some 6 h, similar to sedation. Thus, VTA
Vgat neurons could, in principle, be a target for novel sedatives that promote a sustained NREM-like sleep ( Supplementary Fig. 16 ). It is surprising that this strong sedative effect arising from activating VTA Vgat neurons has not been noticed. Previous work emphasized that activating VTA GABAergic neurons effects motivational states by inhibiting dopamine neurons in the VTA 42 , or by inhibiting cholinergic neurons in the NAc 31 . But in none of these experiments was the EEG recorded, so it is unclear how to interpret the behaviors, especially when decreases in a particular behavior were reported, which could, in fact, be caused by sedation.
Inputs or modulators that physiologically excite VTA Vgat neurons will tend to decrease wakefulness. The LHb is one such nucleus that sends many excitatory glutamatergic projections to GABAergic neurons in the VTA 43 . Thus, strong activation of this LHb pathway would be predicted to induce NREM-like sleep. We have found that the anesthetic propofol requires activation of glutamatergic neurons of the LHb to induce sedation; that is, slow wave (delta) power in the EEG and motor immobility 44 . Downstream of the LHb, this 
Vgat
-hM3Dq mice, and mice were given gabazine 10 min before saline or CNO i.p. injection. Percentages and times for wake were scored (saline: n = 6 mice; gabazine: n = 7 mice; CNO: n = 8 mice; CNO + gabazine: n = 6 mice). *P < 0.05; for e and f, repeated measures two-way ANOVA and Bonferroni-Holm post hoc test. All error bars represent s.e.m. For detailed statistical information, see Supplementary Table 1 .
Articles Nature NeuroscieNce mechanism could include the activation of the VTA Vgat neurons, including those GABAergic cells in the rostromedial tegmental nucleus at the posterior end of the VTA 45 .
As with VTA
Vgat neurons, the extreme wakefulness produced by stimulating VTA Vglut2/Nos1 neurons may not have been noticed before because no EEG analysis was performed. We found that the midline VTA Vglut2/Nos1 neurons promote wakefulness, in part through the NAc and in part through the LH. The VTA Vglut2/Nos1 terminals in the LH could excite GABAergic projection neurons that in turn promote wakefulness 11, 15 , as well as exciting orexin neurons. On the other hand, because lesioning the NAc increases wakefulness 46, 47 , this implies that NAc GABAergic projection neurons limit wakefulness, or are actively inducing NREM sleep. If terminals of VTA DA neurons are stimulated in the NAc, wakefulness is produced 5 . This is similar to stimulating the VTA Vglut2/Nos1 terminals. However, since the wake-promoting effect of VTA Vglut2/Nos1 neurons is not blocked by dopamine receptor antagonists, it could be that the wake-promoting dopamine terminals do so by promoting glutamate release in the NAc. Similar to our findings, the paraventricular thalamus also promotes wakefulness by sending glutamatergic projections to the NAc 17 . It could be that glutamate inputs local GABA neurons in the NAc, which then inhibit the NREM sleep-promoting GABAergic projection neurons. In any case, the NAc is probably a core part of the wake-promoting circuitry. Similar to GABA and glutamate, NOS1 associates with neurons regulating both wakefulness and sleep 21, 48 . A recent report found that Vglut2/Nos1 projection neurons in the supramammillary nucleus promote wakefulness when chemogenetically activated 14 . Our CNO injections to activate mammillary Vglut2 neurons did not increase wakefulness (Fig. 1j) . The reason for the difference is unclear, but in principle there could be a continuous population of Vglut2/Nos1 cells from the VTA through to the supramammillary nucleus.
AAV-DIO-
What is the significance of the VTA Vglut2/Nos1 or the VTA Vgat neurons being REM-active? Activating the VTA Vglut2/Nos1 or the VTA Vgat neurons did not produce REM sleep, and activating VTA Vgat neurons during NREM sleep did not alter REM sleep duration (Fig. 8c) . Therefore, the VTA Vglut2 and VTA Vgat neurons respond to the primary REM sleep-inducing circuitry, but do not induce or maintain REM sleep.
In summary, our findings on VTA Vglut2/Nos1 and VTA Vgat neurons, and other recent discoveries on dopamine VTA neurons 5 , identify the VTA as a critical center regulating wakefulness. The VTA is exceptionally well connected, receiving glutamate and GABA inputs from nearly all brain areas 42, 43, 49, 50 , making it well suited to serve as an integrator of vigilance state. This should be considered when designing experiments to look at the role of the VTA in reward-directed, goal-directed, and social behaviors.
online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41593-018-0288-9. 
Vgat
-ChR2-EYFP mice (control: n = 6 mice; ChR2: n = 5 mice) were given 3 h of optostimulation during the active period ('lights-off' period) and the percentages and times for wake, NREM, and REM sleep were scored. c, Mice were given 5 min of optostimulation when NREM sleep occurred (control: n = 5 mice, 5 trials; ChR2: n = 5 mice, 5 trials). The durations of NREM and REM sleep were scored. **P < 0.01, ***P < 0.001, ****P < 0.0001; for a, two-sided Mann-Whitney U test; for b and c, two-sided unpaired t test. All error bars represent s.e.m. Shaded regions represent s.e.m. For detailed statistical information, see Supplementary 54 . All mice used in the experiments were male and aged 8 weeks at the start of the stereotaxic injections and experiments. Mice were maintained on a 12-h light/12-h dark cycle at constant temperature and humidity with ad libitum food and water.
AAV transgene plasmids. pAAV-hSyn-DIO-hM3Dq-mCherry and pAAV-hSyn-DIO-hM4Di-mCherry were gifts from Bryan L. Roth (Addgene plasmids 44361 and 44362) 55 ; pAAV-CBA-DIO-GFP was a gift from Edward Boyden (Addgene plasmid 28304); pAAV-EF1α -DIO-taCASP3-TEV was a gift from Nirao Shah (Addgene plasmid 45580) 56 . pAAV-EF1α -DIO-hChR2(H314R)-EYFP was a gift from Karl Deisseroth (Addgene plasmid 20298). AAV2/9-CAG-DIO-GCaMP6f was a gift from HanBio Co. and packaged by BrainVTA.
To create pAAV-hSyn-DIO-GCaMP6s, we used the GCaMP6s reading frame from pGP-CMV-GCaMP6s-EGFP (a gift from Douglas Kim 57 , Addgene plasmid 40753). The plasmid pAAV-hSyn-DIO-hM3D q -mCherry (see above) was digested with AscI and NheI, to remove the hM3D q -mCherry reading frame but keeping both sets of loxP sites to give the pAAV-DIO backbone. The modified GCaMP6s reading frame (in-frame mutated to remove AscI and NheI sites) was amplified by PCR from pAAV-hsyn-GCaMP6s, digested with AscI and NheI, and then ligated into the pAAV-DIO backbone to give pAAV-hSyn-DIO-GCaMP6s.
AAV preparation and stereotaxic injections.
To produce AAV (capsid serotype 1/2), the adenovirus helper plasmid pFΔ 6, capsid-plasmids pH21 (AAV1) and pRVI (AAV2), and the relevant pAAV transgene plasmid (see section ' AAV transgene plasmids') were cotransfected into HEK293 cells and the subsequent AAV particles were collected on heparin columns, as described previously 58, 59 .
To produce retro-AAV-DIO-rc(Chronos-GFP), we used the rAAV2 packaging plasmid, a gift from Alla Karpova and David Schaffer 60 (Addgene plasmid 81070), and the helper plasmid pFΔ 6, together with pAAV-EF1α -DIO-rc(Chronos-GFP), a gift from Edward Boyden 61 (Addgene plasmid 62725). These plasmids were cotransfected into HEK293 cells. To purify the retro-AAV we used the AAVpro Purification Kit (all Serotypes) (Takara Clontech, catalog number 6666).
Surgery. Mice were anesthetized with 2% isoflurane in oxygen by inhalation, received buprenorphine injection, and were placed on a stereotaxic frame (Angle Two, Leica Microsystems). The AAV was injected through a stainless steel 33-gauge/15-mm/PST3 internal cannula (Hamilton) attached to a 10-µ l Hamilton syringe, at a rate of 0.1 µ l min After injection, the cannula was left at the injection site for 5 min and then slowly pulled out. After injections, mice were implanted with 3 gold-plated miniature screw electrodes (-1.5 mm Bregma, + 1.5 mm midline; + 1.5 mm Bregma, -1.5 mm midline; -1 mm Lambda, 0 mm midline -reference electrode) with 2 EMG wires (AS634, Cooner Wire). The EMG electrodes were inserted between the neck musculature. The EEG/EMG device was affixed to the skull with Orthodontic Resin Power and Orthodontic Resin Liquid (Tocdental).
For the telemetry EEG and EMG surgery, a TL11M2-F20-EET device (Data Science International) was implanted in the abdominal cavity in mice, four wires of which were subcutaneously led to the mouse's neck by a guiding cannula. Mice were then fixed onto the stereotaxic apparatus in a prone position. A pair of wires was imbedded into the bilateral parietal skulls (AP 0.2 mm, ML 1.5 mm, DV − 0.1 mm; AP − 1.7 mm, ML − 0.2 mm, DV − 0.1 mm) by the dental cement to record EEG. The other pair of wires was implanted in the neck muscles to monitor the EMG. Supplementary Fig. 17 .
For the microendoscopic calcium imaging, Vgat-ires-Cre mice, which had already been injected with AAV2/9-CAG-DIO-GCaMP6f into the VTA, were allowed to recover from surgery for 3 weeks. They were then re-anesthetized with isoflurane and had TL11M2-F20-EET telemetry devices fitted (see other protocols in the Methods section). The skull was coated with ultraviolet-curable resin. After 20 s exposure to ultraviolet light, a protective coating was formed on the skull. A small hole (1-mm diameter) was drilled on the skull (AP − 3.45 mm, ML 1.25 mm). To avoid bleeding or drying of the meninges and brain tissue, saline (0.9% NaCl) was superfused constantly. The tissue drill with a printed circuit board (PCB) bit (500-μ m diameter) was fixed on the stereotaxic frame carefully to remove the brain tissue over the target area. By using a micromanipulator (MP285, Sutter), a GRIN lens (diameter 500 μ m, length 7.6 mm) was slowly implanted into the VTA (AP − 3.3 mm, ML 0.35 mm, DV − 4.15 mm). During the insertion process, the lens stayed still for 10 min for every 1 mm insertion. The lens was then secured by dental cement and the part left outside the skull was covered by tissue glue (KwikSil). One week later, the tissue glue was removed. The camera (nVista, Inscopix) was connected with the lens to check the fluorescence signals, and then the camera base (baseplate) was secured to the skull with dental cement. After surgery, mice were allowed to recover for at least 2 weeks before experiments. The positions of the GRIN lens placements for all mice are shown in Supplementary Fig. 17f .
Behavioral protocols and drug treatments.
For chemogenetic experiments, CNO (C0832, Sigma, dissolved in saline, 1 mg kg −1 ) or saline was injected i.p. and the vigilance states recorded. Mice were split into random groups that received either saline or CNO injection. To test for sleep-promoting effects, we injected saline or CNO during the 'lights off ' period when the mice were likely to be most active; to test for wake-promoting effects, we injected saline or CNO at the start of the 'lights on' period when the mice had their maximum sleep drive. For the PH/MB Note: in all of the Ca 2+ photometry experiments we used GCaMP6s, and for the in vivo microscopy experiments for Ca 2+ imaging we used GCaMP6f. For the photometry experiments, the Ca 2+ signal of VTA
Vglut2
-GCaMP6 or VTA Vgat -GCaMP6 mice was measured for 2-6 h during both the 'lights off ' wake phase and the 'lights on' sleep phase. To challenge the mice with novel objects or females, novel objects or female mice were put in the home cage during the 'lights off ' wake phase and the Ca 2+ signal of the VTA ) and D2/3 receptor antagonists (raclopride 2 mg kg −1 ) and, 30 min after the antagonists' injection, the mice received a saline or CNO (1 mg kg −1 ) i.p. injection, as previously reported 8 . For VTA Vgat -hM3Dq mice, gabazine (0.001 μ g) or saline (300 nl) was infused through a gilded cannula according to a previous study 62 . Then, 10 min after infusion, the mice received saline or CNO (1 mg kg
) by i.p. injection.
Locomotor activity. The locomotor activity was detected in an activity test chamber (Med Associates) with ANY-maze video tracking system. We injected saline or CNO (1 mg kg −1 ) i.p. at the start of the 'lights on' period when the mice had their maximum sleep drive, and we performed the locomotion experiment 30 min after injection. The behavior was recorded by a video tracking system Electrophysiological recording from midline VTA neurons innervated by VTAVgat neurons in VTAVgat-ChR2-EYFP mice. Slices were transferred to a submersion recording chamber and were continuously perfused at a rate of 4-5 ml min −1 with fully oxygenated aCSF at room temperature. For whole-cell recording, patching pipettes at 4-6 MΩ were pulled from autoclaved borosilicate glass capillaries (1.5 mm OD, 0.86 mm ID; Harvard Apparatus, GC150F-10) and filled with RNase-free intracellular solution containing (in mM): 140 K-gluconate, 5 NaCl, 10 HEPES, 0.1 EGTA, 2 MgCl 2 , 2 Mg-ATP, and 0.3 Na-GTP (pH 7.35, osmolality 285 mOsm); or 125 KCl, 20 NaCl, 10 HEPES, 1 EGTA, 1 CaCl 2 , 1 MgCl 2 , 2 Mg-ATP, and 0.5 Na-GTP (pH 7.35, osmolality 285 mOsm). Neurobiotin (0.1%) was included in the intracellular solutions to identify the cell position and morphology following recording. Recordings were performed in current clamp or voltage clamp mode using a Multiclamp 700B amplifier (Molecular Devices). Access and input resistances were monitored throughout the experiments using a 5-mV voltage step. The access resistance was typically < 20 MΩ , and results were discarded if resistance changed by > 20%. Membrane capacitance was measured under voltage clamp at − 50 mV using a hyperpolarizing 10-mV, 250-ms step. Membrane capacitance was measured from the change in membrane charge taken from the integrated capacity transients (pClamp, Molecular Devices).
Non-YPF + neurons (presumed non-VTA Vgat neurons) were visually identified and randomly selected. To maximize RNA recovery, the internal solution in the patch pipette was limited up to 1 µ l. A blue light (470 nM) was delivered by TTLcontrol light-emitting diode to the entire field through the objective. After the stable voltage clamp was achieved, a single 5 ms light pulse was given at the 30 s inter-sweep interval. The light intensity was adjusted according to the magnitude of the response.
At the end of each recording, cytoplasm was aspirated into the patch pipette, and expelled into a PCR tube containing lysate buffer. The single-cell RT-PCR assays were performed using the Single-Cell to CT Kit (Ambion). The content of the neuron was aspirated into the recording pipette and expelled into cell lysis/DNase I solution. Reverse transcription and complementary DNA preamplification were performed according to the kit protocol. Quantitative PCR was performed using the TaqMan Gene Expression Assay system (Applied Biosystems). The mouse TaqMan assay probes were designed by, and purchased from, Invitrogen (ThermoFisher): m18srRNA, Mm03928990_g1; mSlc17a6 (Vglut2) Mm00499876_m1; mSlc6a3 (dat) Mm00438388_m1; mTh Mm00447557_m1; mGad1: Mm04207432_g1; mSlc32a1 (Vgat) Mm00494138_m1. The single-cell gene expression matrix was made by Origin.
Quantification and statistics. All statistical tests were run on Origin 2015 (Origin). The individual tests we used are given in the figure legends and the details are supplied in Supplementary Table 1. All data are given as mean ± s.e.m. unless otherwise stated in the figure legends. No statistical methods were used to predetermine sample sizes but our sample sizes are similar to those reported in previous publications 21, 44 . The data met the assumptions of the statistical tests used. Before using any given statistical test we formally tested for normality and equal variances. When we found that the data were non-normal, we used non-parametric tests (details in the relevant figure legends and in Supplementary Table 1 ). All t-tests were two-sided.
We excluded mice in which it was subsequently found that the opto-fibers were misplaced or that there was no AAV transgene expression, or when this expression was in the wrong place. Mice were assigned randomly to the experimental and control groups. When possible, experimental treatments were also randomized. When mice were given drugs verses saline, for example, they received the drug or saline in random order. All experimental data analysis was blinded, including cFos counting, the analysis of EEG data, and animal behavior that was scored from videos.
Reporting summary. Further information on research design is available in the Life Sciences Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding authors on reasonable request. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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Data collection
To collect sleep-wake data, we used Downloader (Evolocus) and Spike2 (Cambridge Electronic Design) or Dataquest ART (version 4.33); we used WinWCP (Version 4.1.2) and WinEDR (Version 3.0.9) for electrophysiology experiments (Strathclyde Electrophysiology Software) We used video tracking system (ANY-maze) to collect the behavioral data.
Data analysis
We used Spike2 (Cambridge Electronic Design) to analyze sleep-wake data; we used ANY-maze software to analyze behavioral data; we used WinWCP (Version 4.1.2) to analyze electrophysiology data For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Sample size
No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications21,44. The data met the assumptions of the statistical tests used; before using any given statistical test we formally tested for normality and equal variances.
Data exclusions We excluded mice where it was subsequently found that the placement of the opto-fibers was misplaced or if there was no AAV expression, or AAV expression was in the wrong place.
Replication
The results were obtained on at least 3 cohorts of mice. Additionally, some of the results were reproduced independently between the three arms of the collaboration, in the Xijing hospital China and Imperial and Crick labs.
Randomization Mice were assigned randomly assigned to the experimental and control groups. When possible, experimental treatments were also randomized. When mice were given drugs verses saline, for example, they received the drug or saline in random order.
Blinding
All experimental data analysis was blinded, including cFOS counting, the analysis of EEG data and animal behaviour that was scored from videos.
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